<DOC>
	<DOCNO>NCT00431132</DOCNO>
	<brief_summary>This trial conduct Europe . The purpose study evaluate endometrial safety intravaginal estradiol ( Vagifem® ) healthy postmenopausal woman atropic vaginitis .</brief_summary>
	<brief_title>Endometrial Safety Low Dose Vagifem® Postmenopausal Women With Atrophic Vaginitis</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Postmenopausal woman whose last menstruation least two year prior time screen At least 1 urogenital symptom ( vaginal dryness , vaginal and/or vulvar irritation/itching , vaginal soreness , dysuria , dyspareunia vaginal bleeding associate sexual activity Generally healthy Exposure exogenous sex steroid hormone ( estrogen and/or progestin hormone replacement therapy ) within past 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>